The associations of FGF21 and these important risk factors of CAD prompted our current investigation of whether a direct relationship exists between serum FGF21 levels and CAD occurrence in the presence or absence of concomitant NAFLD. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.